ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 9

Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

, , ,
EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP. 5: Exciting Data and Trials in Progress from ASCO 2024
EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
Now Viewing
EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP. 12: The Role of Chemotherapy in nccRCC Treatment
EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP. 14: Final Thoughts/Looking Forward
  1. Please briefly mention the recent retrospective findings with cabo post-len + pembro – (Haro-Silerio, et al. ASCO GU 2024. Abstract 433) = How do you approach treatment post-IO?
  2. Please highlight recent data from the LITESPARK-011 trial(NCT04586231) evaluating belzutifan + lenvatinib vs cabozantinib in advanced RCC after anti-PD-L1 therapy (Motzer, et al. Future Med, 2023

a. Please also briefly mention the significance of recent data from the phase 3 LITESPARK-005 trial (NCT04195750) assessing belzutifan versus everolimus in previously treated advanced RCC patients

i. Safety and Efficacy – (Albiges, et al. ESMO 2023. Abstract LBA88

ii. Patient reported outcomes – (Powles, et al. ASCO GU 2024. Abstract 361)

b.How does belzutifan fit into your treatment paradigm?